Home > Oncology > ESMO 2021 > Breast Cancer > BrighTNess data may change guidelines

BrighTNess data may change guidelines

Presented By
Prof. Sibylle Loibl, German Breast Group, Germany
ESMO 2021
Phase 3, BrighTNess
The long-term follow-up (4.5 years) of the phase 3 randomised BrighTNess trial supported that neoadjuvant carboplatin plus paclitaxel is superior to paclitaxel alone, with high pathologic complete response (pCR) rates and event-free survival (EFS) rate benefits in patients with triple-negative breast cancer, including patients with a germline BRCA mutation. However, the authors also noted that there were no significant differences in overall survival (OS) at this later timepoint. Prof. Sibylle Loibl (German Breast Group, Germany) presented the newest update from the BrighTNess trial (NCT02032277) from patients with previously untreated histologically or cytologically confirmed stage 2 or stage 3 triple-negative breast cancer (n=634) who were candidates for potentially curative surgery and had a good performance status. Pa...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on